SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

Zealand Pharma Zeydovio gets positive EU panel opinion

Zealand Pharma said the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of its short bowel syndrome drug candidate Zeydovio (OMXCOP: ZEAL).

ZEAL

Zealand Pharma OMXCOP:ZEAL said on Friday that the Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of its drug candidate Zeydovio for the treatment of short bowel syndrome. The company said the positive opinion marks the first major advancement in the process.

Related stories